Johnson & Johnson
NYSE:JNJ
Johnson & Johnson
NYSE:JNJ
Price:
240.28
USD
0.27%
Market Closed
Market Cap:
$578.9B
Relative Value
The Relative Value of one
JNJ
stock under the Base Case scenario is
172.87
USD.
Compared to the current market price of 240.28 USD,
Johnson & Johnson
is
Overvalued by 28%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
JNJ
Relative Value
Base Case
172.87
USD
Overvaluation 28%
Multiples Across Competitors
JNJ Competitors Multiples
Johnson & Johnson Competitors
Johnson & Johnson Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD | 6.1 | 21.6 | 15 | 18.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
932.9B USD | 14.3 | 45.2 | 30.5 | 32.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
271B CHF | 4.4 | 21 | 12.4 | 13.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.2B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 5.1 | 29.5 | 16.3 | 23 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
287.1B USD | 4.4 | 15.7 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.7 | 8 | 9.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.8B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121B USD | 2.5 | 17.2 | 7.2 | 8.9 | |
| UK |
|
GSK plc
XETRA:GS71
|
97.2B EUR | 2.6 | 14.8 | 7.5 | 10.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
